Ga68-FAPI-46 PETCT Imaging to Assess Peritoneal Carcinomatosis Before Surgery in Colorectal and Ovarian Cancer

What this Trial Is About

Researchers are evaluating the accuracy of a new imaging method using a radiotracer called Ga68-FAPI-46 in PETCT scans to assess peritoneal carcinomatosis in patients with colorectal and ovarian cancer. This phase II, non-randomized clinical imaging trial studies a protein called Fibroblast Activation Protein FAP, found in the tumor environment. The goal is to see how well this imaging technique detects cancer spread before surgery compared to current methods and surgical findings. The study involves patients who have or are suspected to have peritoneal metastases and are scheduled for complete cytoreductive surgery. Participants receive the Ga68-FAPI-46 radiotracer intravenously, followed by PETCT imaging. Those undergoing neoadjuvant chemotherapy will have scans before and after their treatment. The imaging results will be compared with surgical and histopathological findings to evaluate the methods accuracy. During the study, participants will undergo imaging scans and surgical procedures as part of their standard care. Researchers will compare the cancer spread scores from the Ga68-FAPI-46 PETCT scans with those obtained during surgery and standard imaging. They will also assess how chemotherapy affects the expression of the target protein in tumors. The study lasts up to two years, including follow-up examinations after surgery and chemotherapy.

Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis